BEDFORD, Mass. and SAN DIEGO, April 30, 2012 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) and Gen-Probe Incorporated (NASDAQ: GPRO) today announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion. The all-cash transaction is expected to be funded through available cash and additional financing of term loans and high yield securities. The transaction is expected to be completed in the second half of calendar 2012.

The transaction delivers a strong growth profile with attractive economics and is expected to be $0.20 accretive to Hologic's adjusted earnings per share in the first fiscal year after close and significantly more accretive thereafter. Hologic also expects the transaction to accelerate top and bottom line growth rates. The combined company expects to realize approximately $75 million in cost synergies within three years following the close of the transaction. In addition, the combined company expects to have strong free cash flows, which will be used primarily to reduce debt with the expectation to return to pre-transaction leverage levels within three years.

Gen-Probe is a leader in molecular diagnostics products and services, making it a highly complementary addition to Hologic's growing diagnostics portfolio. The combined company will have pro forma LTM revenues of approximately $2.4 billion, adjusted EBITDA of $822 million (excluding synergies) and offer a wide spectrum of health products globally. The transaction allows Hologic to combine Gen-Probe's superior automation platforms of TIGRIS and PANTHER and extensive menu of sexually transmitted disease (STD) tests, including the APTIMA line of Chlamydia/Gonorrhea (CT/NG), human papillomavirus (HPV) and Trichomonas products, with its strong global market presence and distribution – all targeting women's health.  In addition, Gen-Probe's PROCLEIX line of HIV, HCV, HBV, and West Nile Virus (WNV) blood screening products and strong partnership with Novartis provide an attractive market, with a global reach and significant growth opportunities for the combined company. The combined company expects to create additional value through significant cross-selling opportunities, utilizing the combined global sales force and complementary research and development (R&D) and operational capabilities.

Rob Cascella, President and Chief Executive Officer of Hologic, said, "Gen-Probe is an ideal partner and strategic fit to Hologic's existing diagnostics business and complements our focus on scaling and diversifying our diagnostics franchise. Gen-Probe is a unique player in molecular diagnostics, with best-in-class technology, including the differentiating automation capabilities of TIGRIS and PANTHER, a broad menu of tests, such as the recently approved APTIMA HPV and Trichomonas assays, and a leading blood screening business. This transaction establishes Hologic as a premier company in STD diagnostics and advances our core focus on women's health. With unique capabilities and an impressive new product pipeline, our combined company will be well positioned globally to capitalize on the fast-growing molecular diagnostics market with an established global infrastructure."

Mr. Cascella continued, "Through this compelling transaction, we will achieve critical mass in our core diagnostics business and meet the needs of our customers with a broader portfolio of diagnostics technology, automation and connectivity solutions. With the combination of our capabilities, Hologic will operate a diagnostics franchise with the growth potential similar to our breast health franchise."

Carl Hull, Chairman and Chief Executive Officer of Gen-Probe, said, "This transaction provides compelling cash value for our shareholders and represents an outstanding opportunity for our business. Together, Gen-Probe and Hologic will be very well-positioned to pursue a complete range of diagnostic opportunities in women's health, with a stronger focus on the dynamic molecular diagnostics market. Specifically, we are excited about the opportunity to increase demand for our APTIMA women's health products based on Hologic's global commercial presence. Our employees will benefit as part of a larger diversified organization with the necessary scale and resources to be a leader in today's rapidly evolving global healthcare marketplace."

Strategic Benefits of the Combination

• Enhances breadth of molecular diagnostics portfolio: Gen-Probe's impressive, fully automated product franchise complements and broadens Hologic's offerings in women's health and diagnostics. Gen-Probe adds the marketed instrument brands TIGRIS and PANTHER, as well as the APTIMA line of CT/NG, HPV and Trichomonas assays, to Hologic's diagnostics portfolio. In addition, exciting new products in infectious disease testing and transplant diagnostics provide opportunities for future growth outside of women's health.
• Expands international presence: The combined company will benefit from a broader global presence doing business in a total of over 150 countries. Hologic intends to market Gen-Probe's products on a global basis, focusing in both developed and emerging markets around the world. With Hologic's direct sales and marketing structure in Europe, and its investment in China distribution, the growth trajectory of Gen-Probe's products is significantly enhanced. In particular, Hologic has over 500 employees focused on diagnostics in China. 
• Cross-selling opportunities: The combined company anticipates significant cross-selling opportunities within its diagnostics franchise due to Hologic's extensive channel coverage and the addition of Gen-Probe's best-in-class assays.  Hologic's physician sales team will be instrumental in growing test utilization, driving compliance and communicating screening guidelines to increase overall organic growth.
• Positions combined company for sustained growth: It is anticipated that recent new product introductions will provide sustainable growth for the next several years. In addition the combined pipeline of ongoing initiatives are expected to provide growth into the future.
• Experienced management team and employees: The combination of these businesses brings together the experienced leadership of two successful companies capable of sustaining long term future growth.

Financial Benefits of the Combination

• Strong financial profile and diversified revenue mix: The pro forma LTM revenues of the combined company total approximately $2.4 billion with combined adjusted EBITDA of $822 million, excluding synergies. The combined company will have a diversified portfolio of products with a core focus on diagnostics and breast health, and solid positions in surgical, blood screening and skeletal markets.
• Delivers significant synergies: Hologic expects to realize annual cost synergies of approximately $75 million within three years following the close of the transaction, with approximately $40 million anticipated in the first year after the close of the transaction. Savings are expected to be realized through the alignment of assets to maximize efficiencies and overhead consolidation. In addition, it is anticipated that cross selling opportunities will provide potential for further meaningful revenue enhancement.
• Accretive to earnings: Hologic expects the combination to be $0.20 accretive to Hologic's adjusted earnings per share in the first fiscal year after close and significantly more accretive thereafter. Hologic also expects the transaction to accelerate top and bottom line growth rates.
• Robust free cash flows:  The combined company expects to have strong free cash flows, which will be used primarily to reduce debt, with the expectation to return to pre-transaction leverage levels within three years.

Financing
The all-cash transaction is expected to be funded through available cash and additional financing of term loans and high yield securities. Hologic has secured fully committed financing from Goldman Sachs Bank USA and Goldman Sachs Lending Partners LLC.

Headquarters and Management
Following the close of the transaction, Gen-Probe will become a wholly-owned subsidiary of Hologic. Hologic will retain its headquarters in Bedford, Massachusetts, and the combined company will maintain a significant presence in San Diego, California.

Rob Cascella will continue as President and Chief Executive Officer of Hologic and Carl Hull, Chairman and Chief Executive Officer of Gen-Probe, will oversee the company's combined diagnostics business.

Terms and Approvals
The transaction is expected to close in the second half of calendar 2012 and is subject to the satisfaction of customary closing conditions, including approval of Gen-Probe's shareholders and expiration of the applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and necessary foreign clearances.

Advisors
Goldman, Sachs & Co. and Perella Weinberg Partners are acting as financial advisors to Hologic and Brown Rudnick LLP and Jones Day are acting as legal advisors. Morgan Stanley & Co. LLC is acting as financial advisor to Gen-Probe and Skadden, Arps, Slate, Meagher & Flom LLP and Cooley LLP are acting as legal advisors.

Conference Call and Webcast
Hologic and Gen-Probe management will host a conference call at 8:15 a.m. (Eastern) to discuss today's announcement, Hologic's second fiscal quarter 2012 results and Gen-Probe's first quarter 2012 results. Interested participants may listen to the call by dialing 877-856-1962 (for callers within the U.S.) or 719-325-4863 (for international callers) and referencing code 4975261 approximately 15 minutes prior to the call. The webcast and accompanying slides can be accessed atwww.hologic.com or www.gen-probe.com.

A replay of the call will be available through May 18, 2012 at 888-203-1112 (for callers within the U.S.) or 719-457-0820 (for international callers), access code 4975261, and at www.hologic.com or 
www.gen-probe.com.

Supporting materials for the conference call, including a presentation, will be available on the Investor Relations sections of Hologic's and Gen-Probe's websites at http://investors.hologic.com and www.gen-probe.com, respectively.

About Hologic:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

About Gen-Probe:
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to http://www.gen-probe.com.

Gen-Probe, APTIMA, PANTHER and TIGRIS and associated logos are trademarks and/or registered trademarks of Gen-Probe Incorporated and/or its subsidiaries in the United States and/or other countries.  PROCLEIX is a trademark of Novartis Vaccines & Diagnostics, Inc.

Use of Non-GAAP Financial Measures:
Hologic, Inc. (the "Company") has presented the following non-GAAP financial measures in this press release: adjusted net income and adjusted EBITDA of each of Hologic and Gen-Probe, and pro forma adjusted net income, adjusted EPS and adjusted EBITDA of the combined company.  The Company defines its non-GAAP adjusted net income and adjusted EPS to exclude the non-cash amortization of intangible assets, other acquisition-related charges, such changes for contingent consideration, transaction costs and charges associated with the write-up of acquired inventory to fair value, non-cash interest expense related to amortization of the debt discount for convertible debt securities, divestiture and restructuring charges, non-cash loss on exchange of convertible notes, and one-time, nonrecurring, unusual or unanticipated charges, expenses or gains. The Company's non-GAAP adjusted EBITDA excludes from its GAAP net income: (i) the items excluded in its calculation of non-GAAP adjusted net income; (ii) interest expense, net, not otherwise excluded in calculating its non-GAAP adjusted net income; (iii) provision for income taxes; and (iv) depreciation expense.

The reconciliations of these historical non-GAAP measures to the combined company's comparable GAAP financial measures for the periods presented, are set forth in the supplemental information attached to this press release. Future GAAP EPS may be affected by changes in ongoing assumptions and judgments relating to the combined company's acquired businesses, and may also be affected by nonrecurring, unusual or unanticipated charges, expenses or gains, all of which are excluded in the calculation of non-GAAP adjusted net income, adjusted EPS and adjusted EBITDA as described in this press release. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measure. 

The Company believes the use of these non-GAAP metrics are useful to investors in comparing the results of operations for comparable periods by eliminating certain of the more significant effects of its acquisitions and related activities, non-cash charges resulting from changes in GAAP, and litigation settlement, divestiture and restructuring. These measures also reflect how the Company manages the business internally. In addition to the adjustments included in the calculation of the Company's non-GAAP adjusted EBITDA eliminates the effects of financing, income taxes and the accounting effects of capital spending. As with the items eliminated in its calculation of non-GAAP adjusted net income, these items may vary for different companies for reasons unrelated to the overall operating performance of a company's business. When analyzing the Hologic's, Gen-Probe's and the pro forma combined company's operating performance, investors should not consider these non-GAAP financial measures as a substitute for net income prepared in accordance with GAAP.

Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and Pro Forma EBITDA
(In thousands, except earnings per share)
	Hologic		Gen-Probe
	Twelve Months ended March 24, 2012		Twelve Months ended March 31, 2012		Pro Forma Combined
NET INCOME
GAAP net income	$                   44,304		$                   49,307		$              93,611
Adjustments:
Amortization of  intangible assets	242,124		11,015		253,139
Non-cash interest expense relating to convertible notes	73,598		-	全年征稿 / 资讯合作 联系邮箱：kefu@labbase.net 版权与免责声明 凡本网注明“来源：来宝网”的所有作品，版权均属于来宝网，转载请必须注明来宝网， http://www.labbase.net，违反者本网将追究相关法律责任。 本网转载并注明自其它来源的作品，目的在于传递更多信息，并不代表本网赞同其观点或证实其内容的真实性，不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时，必须保留本网注明的作品来源，并自负版权等法律责任。 如涉及作品内容、版权等问题，请在作品发表之日起一周内与本网联系，否则视为放弃相关权利。 编辑推荐 圣湘表示，2021年新冠已出货1.5亿人份，国内增长超1倍以上！ 华大建设塞尔维亚首座基因测序中心，塞总理布尔纳比奇揭幕 华大基因在埃塞俄比亚设立IVD工厂 迈瑞医疗、万孚生物达成技术合作伙伴战略合作协议 诺唯赞于今日在上交所上市 强生医疗将拆分 百年GE即将一拆三,医疗单独成立公司专注精准医疗 惠斯安普功能医学设备助力打造“全民健康管理示范医院”新样板 博科控股集团有限公司与济南大学举行战略合作签约仪式 博科控股集团与赛默飞世尔签订中国经销商协议 焦点资讯 科德角国际：CNAS权威认证赋能药品全球流通，一站式细菌内毒素检测解决方案领航者 冻干机冻干柠檬，让维C不流失 英国安得仁Anderen公司国内代理是哪家 移动式车载气动升降桅杆 内置线大功率高位伸缩杆 带气泵 泰安迎金学校旋转门图片样式多样化 泰安迎金学校旋转门做好哪些准备 深度评审促提升！旭化成医疗器械（杭州）有限公司对我司开展现场评审 泰安迎金学校开门机选购及保养指南 中国航天日 | 维拓启创与中国航天的十年 当音乐遇见脑科学：使用功能性近红外光谱（fNIRS）探索交响乐团演奏时，音乐诱发演奏者的脑活动 推荐供应 HJ/T 104-2003 BC-50A干法总有机碳(TOC)分析仪 在使用时的操作规范：1,2-二肉豆蔻酸甘油酯-聚乙二醇-羟基（DMG-PEG-OH） BC-50A便携总有机碳分析仪 骨密度检测仪厂家直销OSTEOKJ7000A+ 二氧化碳细胞恒温培养摇床 CO2-250-1C 光纤耦合LED DMG-PEG-COOH；DMG：提供疏水性，可嵌入脂质体的双层膜中 ErgoLAB基于WEB桌面端原型手指轨迹可用性测评系统 ErgoHMI Web手指轨迹测试仪 红外激光显示卡 品牌产品库－ 技术资料－ 厂商－ 产品库－ 供应信息库 关于我们| 网站导航| 本站服务| 会员服务| 法律声明| 友情链接 增值电信业务经营许可证B2-20090004 ICP备案号：鲁ICP备10004482号-1